BioNTech (NASDAQ:BNTX) Stock Price Target Lowered at UBS Group

Key Points

• UBS lowered BioNTech’s price target from $135 to $125 but maintained its Buy rating; the new target implies about 37.8% upside from the cited share price.
• Analyst sentiment overall was Moderate Buy, with an average price target of $123.60. Among the cited ratings, 12 analysts rated the stock Buy, five Hold and one Sell.
• Shares rose 4.3% to $90.70 on Wednesday. In its latest reported quarter in the article, BioNTech missed EPS and revenue estimates, with revenue down 59.5% year over year.

BioNTech (NASDAQ:BNTX - Get Free Report) had its price objective decreased by analysts at UBS Group from $135.00 to $125.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. UBS Group's target price indicates a potential upside of 37.82% from the stock's current price.

Several other brokerages have also commented on BNTX. Wall Street Zen lowered shares of BioNTech from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Weiss Ratings reissued a "sell (d-)" rating on shares of BioNTech in a research report on Friday, October 2nd. Canaccord Genuity Group dropped their target price on shares of BioNTech from $136.00 to $132.00 and set a "buy" rating on the stock in a research report on Wednesday, October 14th. Bank of America reaffirmed a "buy" rating on shares of BioNTech in a report on Wednesday. Finally, Berenberg Bank set a $140.00 price objective on shares of BioNTech in a research note on Wednesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $123.60.

BioNTech Stock Up 4.3%

BNTX stock traded up $3.78 on Wednesday, hitting $90.70. 1,352,767 shares of the company's stock were exchanged, compared to its average volume of 1,094,356. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The firm has a 50 day moving average price of $96.14 and a two-hundred day moving average price of $96.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The stock has a market cap of $22.94 billion, a P/E ratio of -11.58 and a beta of 1.28.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts' consensus estimates of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business had revenue of $122.31 million during the quarter, compared to analysts' expectations of $180.18 million. During the same quarter last year, the business posted ($1.60) earnings per share. The company's quarterly revenue was down 59.5% compared to the same quarter last year. As a group, equities research analysts expect that BioNTech will post -6.62 EPS for the current fiscal year.

Insiders Place Their Bets

In other BioNTech news, CEO Ugur Sahin sold 72,000 shares of the firm's stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $97.23, for a total transaction of $7,000,560.00. Following the completion of the transaction, the chief executive officer directly owned 108,209 shares of the company's stock, valued at approximately $10,521,161.07. This trade represents a 39.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 807,209 shares of company stock valued at $79,246,837. 19.20% of the stock is currently owned by corporate insiders.

Institutional Trading of BioNTech

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Headlands Technologies LLC acquired a new position in BioNTech in the 2nd quarter valued at $2,520,000. Bank of America Corp DE boosted its stake in BioNTech by 22.6% during the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company's stock worth $80,261,000 after purchasing an additional 166,432 shares during the last quarter. Amundi grew its holdings in shares of BioNTech by 24.5% during the first quarter. Amundi now owns 129,513 shares of the company's stock worth $11,511,000 after buying an additional 25,506 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of BioNTech by 79.7% during the third quarter. Assenagon Asset Management S.A. now owns 760,675 shares of the company's stock worth $74,774,000 after buying an additional 337,412 shares in the last quarter. Finally, Flossbach Von Storch SE purchased a new stake in shares of BioNTech during the second quarter worth $207,142,000. Institutional investors and hedge funds own 15.52% of the company's stock.

Trending Headlines about BioNTech

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: BioNTech reported Q3 EPS of $1.99 versus analysts’ $0.76 estimate and revenue of $1.49 billion versus $1.17 billion expected. It raised its 2026 revenue guidance to €1.7–€1.9 billion and reported €16.2 billion in cash, cash equivalents and investments. BioNTech beats third-quarter forecasts and raises revenue guidance despite pipeline setbacks
• Positive Sentiment: Clinical updates offered potential support for BioNTech’s oncology strategy: the company reported promising survival data for gotistobart in previously treated squamous non-small cell lung cancer and advanced a Phase 3 trial of pumitamig in triple-negative breast cancer. It also launched its updated COVID-19 vaccine in multiple regions. BioNTech third-quarter results and corporate update
• Neutral Sentiment: Morgan Stanley lowered its price target from $114 to $106, and Wells Fargo cut its target from $140 to $125. Both firms maintained Overweight ratings, indicating continued optimism despite reduced targets. Morgan Stanley recommendations Wells Fargo recommendations
• Negative Sentiment: A Seeking Alpha analysis downgraded the stock to Hold, citing ongoing cash burn, a narrowing pipeline and reliance on pumitamig and gotistobart. It argued that declining liquid assets and concentrated development bets remain risks despite reported quarterly profit. BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing medicines and vaccines based on messenger RNA and other immunotherapy technologies. The company's research programs address cancer, infectious diseases, and other serious medical conditions.

BioNTech's oncology portfolio includes individualized and off-the-shelf cancer immunotherapies, including mRNA-based treatments, cell therapies, antibody-based therapies, and immune-modulating approaches. Its infectious-disease activities include vaccine programs developed through proprietary platforms and collaborations.

In collaboration with Pfizer, BioNTech developed Comirnaty, an mRNA-based COVID-19 vaccine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.